Rxsight Stock EBITDA
| RXST Stock | USD 50.38 0.81 1.63% |
Rxsight fundamentals help investors to digest information that contributes to Rxsight's financial success or failures. It also enables traders to predict the movement of Rxsight Stock. The fundamental analysis module provides a way to measure Rxsight's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rxsight stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -45.8 M | -48.1 M |
Rxsight | EBITDA |
Rxsight Company EBITDA Analysis
Rxsight's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Rxsight EBITDA | (45.84 M) |
Most of Rxsight's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rxsight is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rxsight EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Rxsight is extremely important. It helps to project a fair market value of Rxsight Stock properly, considering its historical fundamentals such as EBITDA. Since Rxsight's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rxsight's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rxsight's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Rxsight Ebitda
Ebitda |
|
According to the company disclosure, Rxsight reported earnings before interest,tax, depreciation and amortization of (45.84 Million). This is 105.22% lower than that of the Health Care Equipment & Supplies sector and 107.13% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.18% higher than that of the company.
Rxsight EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rxsight's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rxsight could also be used in its relative valuation, which is a method of valuing Rxsight by comparing valuation metrics of similar companies.Rxsight is currently under evaluation in ebitda category among its peers.
Rxsight ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rxsight's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rxsight's managers, analysts, and investors.Environmental | Governance | Social |
Rxsight Institutional Holders
Institutional Holdings refers to the ownership stake in Rxsight that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rxsight's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rxsight's value.| Shares | Bank Of America Corp | 2024-06-30 | 755.3 K | Driehaus Capital Management Llc | 2024-06-30 | 706.2 K | Geode Capital Management, Llc | 2024-06-30 | 694.3 K | Gilder Gagnon Howe & Co Llc | 2024-06-30 | 605.5 K | Nuveen Asset Management, Llc | 2024-06-30 | 559.1 K | Next Century Growth Investors Llc | 2024-06-30 | 528.3 K | Atika Capital Management Llc | 2024-06-30 | 402.6 K | Baillie Gifford & Co Limited. | 2024-06-30 | 358.2 K | No Street Gp Lp | 2024-06-30 | 350 K | Ra Capital Management, Llc | 2024-06-30 | 3.7 M | Blackrock Inc | 2024-06-30 | 2.4 M |
Rxsight Fundamentals
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 39.68 M | ||||
| Shares Owned By Insiders | 5.15 % | ||||
| Shares Owned By Institutions | 88.15 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Earning | 42.55 X | ||||
| Price To Book | 7.15 X | ||||
| Price To Sales | 17.08 X | ||||
| Revenue | 89.08 M | ||||
| Gross Profit | 21.33 M | ||||
| EBITDA | (45.84 M) | ||||
| Net Income | (48.61 M) | ||||
| Cash And Equivalents | 128.62 M | ||||
| Cash Per Share | 4.65 X | ||||
| Total Debt | 3.01 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 11.54 X | ||||
| Book Value Per Share | 6.95 X | ||||
| Cash Flow From Operations | (43.83 M) | ||||
| Short Ratio | 4.84 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 64.86 | ||||
| Number Of Employees | 374 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.97 B | ||||
| Total Asset | 182.55 M | ||||
| Retained Earnings | (594.64 M) | ||||
| Working Capital | 147.5 M | ||||
| Net Asset | 182.55 M |
About Rxsight Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rxsight's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rxsight using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rxsight based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.